Close Menu

distribution agreement

Lucence's test are designed to detect DNA fragments shed by a tumor into the blood and target the most common cancers in Asia such as lung cancer.

The battery-operated, hand-held device uses a broad-spectrum photometric method to provide accurate hemoglobin measurements in about one second.

The deal cover's Sienna's in vitro diagnostic for the detection of the hTERT component of telomerase, a biomarker that aids in the diagnosis of bladder cancer.

As part of the agreements, the distributors have committed to purchase a minimum number of Curetis' molecular diagnostic systems over three years.

HalioDx's Immunoscore Colon is designed to measure the density of two T lymphocyte populations to help physicians assess colon cancer prognosis.

The deal comes a little more than month after the companies agreed to form a joint venture that will develop a blockchain-based healthcare service platform.

The system is designed to provide a quantitative determination of red blood cells and total nucleated cells in CSF.

The lab will make Lucence's non-invasive cancer tests available to patients in the region, but financial and other terms were not disclosed.

The company will supply the Chinese laboratory with its ClearCell FX1 system and help train and assist its new partner in developing cancer tests.

The company's assay, performed on FFPE tissue, measures the density of two T lymphocyte populations to help physicians assess disease prognosis.

Pages